Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Most children who present with acute onset of barky cough, stridor, and chest-wall indrawing have croup. A careful history and physical examination is the best method to confirm the diagnosis and to rule out potentially serious alternative disorders such as bacterial tracheitis and other rare causes of upper-airway obstruction. Epinephrine delivered via a nebuliser is effective for temporary relief of symptoms of airway obstruction. Corticosteroids are the mainstay of treatment, and benefit is seen in children with all levels of severity of croup, including mild cases.

Croup is a common childhood disease characterised by sudden onset of a distinctive barky cough that is usually accompanied by stridor, hoarse voice, and respiratory distress resulting from upper-airway obstruction. Although most children with croup are deemed to have a mild and short-lived illness, the distress and disruption that families undergo is well known. Perhaps this upset is because of the nature of croup: the presentation is so unusual and frightening and predominantly affects young children, with symptoms that are usually worse during the early hours of the morning. Historically, before the advent of treatment with corticosteroids and racemic epinephrine for severe croup, intubation, tracheotomy, and death were typical outcomes. Treatment has evolved from barbaric methods including bleeding and application of leeches, through mist kettles (pot of boiling water), mist rooms, and mist tents, to the current evidence-based practice of corticosteroids and epinephrine delivered via nebuliser.

Many unanswered questions linger. Why are croup symptoms worse at night? What predisposes some children to severe croup and others to a mild barky cough? What accounts for the stubbornly predictable biannual peak in the occurrence of croup? Is the cause of croup evolving as new viral triggers are identified? Is bacterial tracheitis a new emerging complication of croup? In this Seminar, we summarise the most current published work about the epidemiology, diagnosis, and management of this important childhood disease and propose future research pathways for exploration.

Epidemiology, clinical course, and pathophysiology

Croup is one of the most frequent causes of acute respiratory distress in young children. The disease mainly affects those aged between 6 months and 3 years old, with a peak annual incidence in the second year of life of nearly 5%. However, croup does occur in babies as young as 3 months old and in adolescents. Although rare, adults can also develop croup symptoms. Boys are more susceptible than girls to the disorder, with an overall male/female preponderance of 1:4-1:1. In North America, croup season peaks in late autumn (September to December), but cases are recognised throughout the year, even during the summer. In odd-numbered years, the number of children admitted with croup during the peak season is about 50% more than during even-numbered years, which closely correlates with the prevalence of parainfluenza virus infection in the community (North America).

Symptom onset is typically abrupt and most usually happens at night, heralded by the appearance of a very characteristic and distinctive barky cough. Stridor, hoarse voice, and respiratory distress are seen frequently, as a result of upper-airway obstruction. These symptoms are frequently preceded by non-specific upper-respiratory-tract symptoms for 12–48 h before development of the barky cough and difficulty breathing. Croup symptoms are generally short-lived, with about 60% of children showing resolution of their barky cough within 48 h. However, a few children continue to have symptoms for up to 1 week.

Croup symptoms nearly always become worse during night-time hours, and in our experience they fluctuate in severity depending on whether the child is agitated or calm. We do not know why croup symptoms tend to worsen at night, but a physiologically plausible explanation might lie with the known circadian fluctuations in endogenous serum cortisol, concentrations of which peak at about 0800 h and reach a trough between 2300 h and 0400 h. In asthma, another frequent respiratory disease in which night-time symptoms generally prevail, postulated mechanisms include detrimental effects of nocturnal airway cooling, gastro-oesophageal reflux, and increased tissue inflammation in addition to the effect of endogenous plasma cortisol and epinephrine cycling. Perhaps similar physiological factors are at play in croup.

The symptoms of croup result from upper-airway obstruction caused by an acute viral infection, most
Seminar

Epithelium, contributing to airway oedema. 21 The inhibits sodium absorption across the tracheal Parainfluenza virus also activates chloride secretion and croup, in children with severe measles. 18, 19 The rarity of effective for prevention of secondary infections, especially with vitamin A has been assessed and reported to be cause of croup in non-immunised children. Treatment and croup in children. 10, 11 Whether or not new pathogens metapneumovirus and coronavirus HCoV-NL63 infection association has been described between both human influenzae and Alberta, Canada, about 85% were classified as having mild croup and fewer than 1% as having severe croup (unpublished data). Even though most children have fairly mild symptoms, the sudden onset of croup symptoms during the night causes many parents to bring their child to an emergency department. 24, 25 Consistent with these findings, fewer than 5% of children with croup are admitted to hospital in population-based studies. 26–27 Of those with croup who are admitted, 1–3% are intubated. 26–31 Mortality seems to be very rare. By extrapolation of data from several sources, 26–31 we estimate a mortality rate of about 1 in 30 000 cases.

Differential diagnosis

In a child presenting with classic signs and symptoms of croup, alternate diagnoses are uncommon (panel). However, clinicians must remain vigilant because other serious diseases can present with stridor and respiratory distress.

Panel: Differential diagnosis of croup

• Epiglottitis
• Bacterial tracheitis
• Foreign-body aspiration
  • Tracheal
  • Oesophageal
• Retropharyngeal abscess
• Peritonsillar abscess
• Angioneurotic oedema
• Allergic reaction
• Laryngeal diphtheria

Bacterial tracheitis is a serious, life-threatening bacterial infection that can arise after an acute, viral respiratory-tract infection. 24–27 The child usually has a mild-to-moderate illness for 2–7 days but then becomes acutely worse. 26 If they are febrile, have a toxic appearance (ie, look unwell and have reduced interaction with their environment), and do not respond favourably to treatment with nebulised epinephrine, bacterial tracheitis should be considered. 26–31 Treatment includes close monitoring of the airway and broad-spectrum intravenous antibiotics, because intubation and respiratory support might be needed during the early stages of treatment when thick tracheal secretions can occlude the airway. The most frequently isolated pathogen is Staphylococcus aureus, but others include group A streptococcus, Moraxella catarrhalis, Streptococcus pneumoniae, and Haemophilus influenzae. 26–31 Anaerobic bacteria have also been cultured from tracheal secretions of children with tracheitis. 26

A second potentially life-threatening alternate diagnosis is epiglottitis. This disease is now seen rarely owing to widespread immunisation against H influenzae B. 26–44 The sudden onset of high fever, drooling,
dysphagia, anxiety, and a preference to sit upright and in the so-called sniffing position (ie, sitting forward with their head extended) to open the airway should prompt consideration of epiglottitis, as should a cough that does not have the characteristic barking sound of croup. In the case of possible epiglottitis or bacterial tracheitis, the most important aspect of treatment is maintenance of a secure airway by a doctor highly skilled in airway management.

Other very rare causes of stridor that should be considered in children presenting with symptoms include foreign-body aspiration in the upper airway or oesophagus, peritonsillar or retropharyngeal abscess, angio-oedema, and laryngeal diphtheria. In the case of foreign-body aspiration, onset is usually sudden with no prodrome or fever (unless secondary infection occurs). Hoarseness and barking cough are usually absent. Dysphagia could be present and stridor is noted variably. Children who have stridor secondary to the presence of a foreign body usually present with a clear history of ingestion. Peritonsillar or retropharyngeal abscess could present with dysphagia, drooling, stridor, dysphnoea, tachypnoea, neck stiffness, and unilateral cervical adenopathy, and a lateral neck radiograph can show posterior pharyngeal oedema and retroflexed cervical vertebrae. Acute angioneurotic oedema or allergic reaction can present at any age and with rapid onset of dysphagia and stridor and possible cutaneous allergic signs such as urticarial rash. Children might have a history of allergy or previous attack. Laryngeal diphtheria has arisen historically in people of all ages, and a record of inadequate immunisation can be seen. Usually, a prodrome of pharyngitis symptoms is noted and onset is gradual over 2–3 days. Low-grade fever is present, hoarseness and barking cough occur along with dysphagia and inspiratory stridor, and the characteristic membranous pharyngitis is seen on physical examination.

Diagnosis and ancillary testing
Croup is a clinical diagnosis. Key features include acute onset of a seal-like barking cough, stridor, hoarseness, and respiratory distress. Children might have fever, occasionally reaching a temperature as high as 40°C, however, they should not drool nor appear toxic. Laboratory tests are not needed to confirm the diagnosis in a child presenting with the typical clinical features of croup, but if tests are judged necessary they should be deferred if the child is in respiratory distress. Notably, rapid antigen tests and viral cultures do not aid in the routine acute management of a child with croup.

Similarly, radiological studies are not recommended in a child who has a typical history of croup and who responds appropriately to treatment. Radiographs are not indicated if there is a clinical picture of epiglottitis or bacterial tracheitis. In children in whom the diagnosis is uncertain, however, an anteroposterior and lateral soft-tissue neck radiograph can be helpful in supporting an alternative diagnosis. If radiographs are obtained, however, epiglottitis is suggested by a thickened epiglottis and aryepiglottic folds. A retropharyngeal abscess is indicated by bulging soft tissue of the posterior pharynx. Bacterial tracheitis can manifest as a ragged tracheal contour or a membrane spanning the trachea. However, radiographs can also be completely normal in children with these diagnoses. If radiographs are justified by an atypical clinical picture, the child must be closely monitored during imaging by skilled personnel with appropriate airway management equipment, because airway obstruction can worsen rapidly.

Cardiorespiratory monitoring, including continuous pulse oximetry, is indicated in children with severe croup but it is not necessary in mild cases. Also, children without severe croup could occasionally have low oxygen saturation, presumably as a result of intrapulmonary involvement of their viral infection; thus, ongoing assessment of overall clinical status is important.

Assessment of severity
Determination of disease severity relies on clinical assessment. Various proposed methods for objective assessment of respiratory distress in children with croup are either impractical or insensitive to change across the full range of disease severity. Consequently, in clinical trials of treatment effectiveness, outcome measures have mainly included clinical scores and health-care use. Although such scores are useful for research studies, none has been shown to enhance routine clinical care, at least in part, because they are not reliable when used by a wide range of clinicians. Features useful in routine clinical assessment of children with croup as outlined in the figure.

General care
General consensus is that children with croup should be made as comfortable as possible, and clinicians should take special care during assessment and treatment not to frighten or upset them because agitation causes substantial worsening of symptoms. Sitting the child comfortably in the lap of a parent or caregiver is usually the best way to lessen agitation.

Although we could not find any published evidence that oxygen should be administered to children who are showing signs of respiratory distress, widespread consensus indicates that oxygen treatment is beneficial in this circumstance. Oxygen can generally be administered without causing the child to be agitated via a plastic hose with the opening held within a few centimetres of the nose and mouth (referred to as blow-by oxygen).

Humidified air
Treatment of croup with humidified air is not effective, despite its long history of use. Humidification of air is
Algorithm for management of croup in the outpatient setting

**Mild** (without stridor or significant chest-wall indrawing at rest)
- Give oral dexamethasone (0.6 mg/kg of bodyweight)
- Educate parents
  - Anticipated course of illness
  - Signs of respiratory distress
  - When to seek medical attention
- May discharge home without further observation

**Moderate** (stridor and chest-wall indrawing at rest without agitation)
- Minimise intervention
  - Place child on parent’s lap
  - Provide position of comfort
- Give oral dexamethasone (0.6 mg/kg of bodyweight)
- Observe for improvement

**Severe** (stridor and indrawing of the sternum with agitation or lethargy)
- Minimise intervention
  - Place child on parent’s lap
  - Provide “blow-by” oxygen
    (optional unless cyanosis is present)
- Give oral dexamethasone (0.6 mg/kg of bodyweight)
- Contact paediatric intensive-care unit for further management

**Persistent mild symptoms**
- No recurrence of:
  - Chest-wall indrawing
  - Stridor at rest
  - Educate parents (as for mild croup)
- Discharge home

**Recurrence of severe respiratory distress**
- Repeat nebulised epinephrine
  - If good response continue to observe
- Consider admission (general ward) if:
  - Stridor at rest
  - Chest-wall indrawing
    (if the patient has recurrent severe episodes of agitation or lethargy)
  - Contact paediatric intensive-care unit

**Poor response to nebulised epinephrine**
- Repeat nebulised epinephrine
- Contact paediatric intensive-care unit for further management

**Good response to nebulised epinephrine**
- Observe for 2 h
- Discharge home

**Clinical outcomes**

- **Pharmacotherapy**
- **Heliox**
- **Mist tents**

---

Figure: Algorithm for management of croup in the outpatient setting
Reprinted from reference 48 with permission.

Neither completely benign nor does it improve respiratory distress. A systematic review of findings of three randomised controlled trials of humidified air treatment in emergency settings in a total of 135 children with mild-to-moderate croup concluded that there was no difference in croup score after such treatment. This systematic review did not include a later randomised controlled trial of 140 children with moderate-to-severe croup in a paediatric emergency department who were randomised to three arms: traditional standard humidified blow-by oxygen; 40% humidified oxygen; or 100% humidified oxygen, with a particle size generated to target the larynx. Measurement of humidified blow-by oxygen showed that this technique did not raise humidity above that of ambient room air, thus effectively serving as a placebo arm. The findings showed no difference in croup score, treatment with epinephrine or dexamethasone, or admission to hospital or additional medical care between the three groups.

Apart from the lack of noted benefit, several potential difficulties with administration of humidified air have been identified. Hot humidified air can cause scald injuries; mist tents can disperse fungus and moulds into the environment unless they are properly cleaned; and most importantly, mist tents are cold and wet and separate the child from the parent, which usually causes them to be agitated and worsens their symptoms.

Heliox is an inert low-density gas with no inherent pharmacological or biological effects. Administration of helium-oxygen mixture (heliox) to children with severe respiratory distress can reduce their degree of distress since the lower density helium gas (vs nitrogen) decreases airflow turbulence through a narrow airway. Heliox was compared with racemic epinephrine in a prospective randomised controlled trial of 29 children with moderate-to-severe croup who had received treatment with humidified oxygen and intramuscular dexamethasone. Clinical outcomes included a clinical croup score, oxygen saturation, and heart and respiratory rates. Both heliox and racemic epinephrine were associated with similar improvements in croup score over time. Findings of a second prospective, randomised, double-blind controlled trial in 15 children with mild croup presenting to an emergency department indicated a trend towards greater improvement in a clinical croup score in the heliox group versus the oxygen-enriched air group, although the scores did not differ significantly. However, since heliox has yet to be shown to offer greater improvements than standard treatments and can be difficult to use in unskilled hands, there is insufficient reason to recommend its general use in children with severe croup. Furthermore, there are practical limitations to heliox use, including limited fractional concentration of inspired oxygen in a child with significant hypoxia.
and several other categories of drugs, such as antipyretics, analgesics, antibiotics, β agonists, and decongestants. The rationale for review of this latter group of drugs is that, although these treatments are not recommended, they are sometimes used in children with croup.84

Corticosteroids

Corticosteroids have a long history of use in children with croup; evidence for their effectiveness for treatment of croup is now clear (tables 1–4). Children with severe croup and impending respiratory failure who are treated with corticosteroids have about a fivefold reduction in the rate of intubation;86 if they are intubated, they remain ventilated for about a third less time and have a sevenfold lower risk for reintubation than patients not treated with these drugs.89 In moderate-to-severe croup patients who are treated with corticosteroids, an average 12-h reduction in the length of stay in the emergency department or hospital, a 10% reduction in the absolute proportion treated with nebulised epinephrine, and a 50% reduction for both the number of return visits and admissions for treatment.60

Compared with children not treated with corticosteroids, those with mild croup who are treated with these drugs are 50% less likely to return for medical care because of ongoing symptoms and lose 30% less sleep during the course of their illness, and their parents report less stress than do parents of children not treated with corticosteroids.87 Treatment with these drugs also yields small but clinically important societal economic benefits (family and health-care system), resulting in a total saving of CAN$21 per child.87 The benefits of treating children with mild croup arise irrespective of the duration of the child’s symptoms or severity of illness.87

To date, no adverse effects have been associated with use of corticosteroids in children with croup.41 However, difficulties arise when attempting to identify and prove that rare adverse effects arise with any drug treatment; thus, remaining vigilant about this possibility is important.

**Route of administration**

The best route of administration of corticosteroids in children with croup has been investigated extensively.

| Studies (n) | Patients (n) | Treatment | Outcomes | Results* |
|------------|--------------|-----------|----------|----------|
| Griffin (2000) | 8 | 574 | Nebulised corticosteroid | Primary: change in clinical croup score 5 h after treatment | Improvement (RR 1.48 [1.27–1.74]) |
| | | | | Secondary: admission | Reduction (RR 0.56 [0.42–0.75]) |
| Kairys (1989) | 10 | 1286 | Oral or intramuscular corticosteroid | Primary: proportion of patients improved at 12 h and 24 h post-treatment | Improvement at 12 h (OR 2.25 [1.66–3.06]) |
| | | | | Secondary: incidence of endotracheal intubation | Improvement at 24 h (OR 3.19 [1.70–5.99]) |
| Russell (2004) | 31 | 3736 | Oral, intramuscular, or nebulised corticosteroid | Primary: change in clinical croup score 6 h after treatment | Improvement (weighted mean difference –1.2 [–1.6 to –0.8]) |
| | | | | Secondary: return to medical care; length of stay in emergency department or hospital; nebulised epinephrine treatment | Reduction (RR 0.5 [0.36–0.70]) |

*Data are relative risk (RR), odds ratio (OR), with 95% CI, unless otherwise stated.

Table 1: Meta-analyses of the effectiveness of corticosteroid treatment versus placebo in croup

| Patients (n) | Croup severity | Setting | Route of administration and medication | Primary outcome | Results |
|--------------|----------------|---------|---------------------------------------|----------------|---------|
| Bjornson (2004) | 720 | Mild | Emergency department | Oral dexamethasone vs placebo | Return to medical care within 7 days | Reduction (7% vs 15%, p<0.001) |
| Geelhoed (1996) | 100 | Mild | Emergency department | Oral dexamethasone vs placebo | Return to medical care within 7–10 days after study treatment | Reduction (0% vs 17%, p<0.01) |
| Johnson (1998) | 144 | Moderate to severe | Emergency department | Nebulised budesonide or intramuscular dexamethasone vs placebo | Rate of admission | Reduction (35% vs 67%, p<0.001) |
| Tibballs (1992) | 70 | Respiratory failure or intubated | Intensive-care unit | Oral prednisolone vs placebo | Duration of intubation | Reduction (median 98 vs 138 h, p=0.003) |
| Geelhoed (1995) | 80 | Moderate to severe | Admitted children | Nebulised budesonide or oral dexamethasone vs placebo | Duration of admission | Reduction (12/13 h vs 20 h, p=0.03) |
| Klassen (1994) | 54 | Mild to moderate | Emergency department | Nebulised budesonide vs placebo | Clinical croup score at 4 h | Improvement (18% vs 6%, p=0.005) |

Table 2: Selected randomised controlled trials of corticosteroid versus placebo in the treatment of croup
The oral or intramuscular route is either equivalent or superior to inhalation. The addition of inhaled budesonide to oral dexamethasone in children admitted with croup did not confer any additional advantage.

In two trials in which oral and intramuscular administration of dexamethasone were compared, no difference was recorded in resolution of croup symptoms, return for medical care, admission to hospital, or further treatment with corticosteroid or epinephrine. Findings of a study comparing intramuscular dexamethasone to oral prednisolone; no difference was noted in reduction of croup score after treatment, hospital admission, time to symptom resolution, or return for medical care.

Studies in which corticosteroids have been administered orally have mainly incorporated dexamethasone. Two comparator studies have been published of oral agents in the treatment of croup. In the first, one oral dose of prednisolone was compared with dexamethasone, and the findings showed superiority of dexamethasone in reducing rates of return for medical care. In the second study, oral dexamethasone was compared with oral prednisolone; no difference was noted in reduction of croup score or rates of return for medical care. A more practical consideration could be that oral dexamethasone is associated with less vomiting than oral prednisone, a substantial advantage.

Practical issues should also be considered. For instance, for a child with persistent vomiting, the inhaled or intramuscular route for drug delivery might be preferable.

In cases of severe respiratory distress, oral administration could be more difficult for the child to tolerate than an intramuscular dose. In a child with hypoxia, decreased gut and local tissue perfusion can impair absorption via the oral or intramuscular route, respectively. In these cases, the inhaled route should be considered and would also allow for administration of oxygen or racemic epinephrine concurrently. The cost of each treatment route should also be thought about.

Drug dosing
With respect to dosing of corticosteroids, two important questions should be asked. First, is one dose of dexamethasone sufficient or will several be required? Second, what is the appropriate size of dexamethasone dose: 0·15 mg/kg, 0·30 mg/kg, or 0·60 mg/kg?

We did not find any randomised trials via our literature search in which single and multiple doses of corticosteroids were compared. Published randomised trials of the effectiveness of corticosteroids are roughly split in terms of using either one dose or several. Theoretically, since most children's croup symptoms resolve within 72 h, and the speculated duration of...

### Table 3: Selected randomised controlled trials of corticosteroid treatment of croup by route of administration

| Patients (n) | Croup severity | Setting | Route of administration | Primary outcome | Results |
|--------------|----------------|---------|--------------------------|----------------|---------|
| Geelhoed (1995) | 80 Moderate to severe | Admitted | Nebulised budesonide vs oral dexamethasone | Duration of admission | No difference between budesonide (13 h) and dexamethasone (12 h) |
| Johnson (1998) | 144 Moderate to severe | Emergency | Nebulised budesonide vs intramuscular dexamethasone | Rate of admission | No difference between dexamethasone and budesonide (17% vs 35%; p=0.18) |
| Klassen (1998) | 198 Moderate | Emergency | Oral dexamethasone vs nebulised budesonide | Clinical croup score at 4 h | No difference between groups (p=0.70) |

### Table 4: Comparison of dosing in selected randomised controlled trials of corticosteroid treatment of croup

| Patients (n) | Croup severity | Corticosteroid and dose | Route of administration | Primary outcome | Results |
|--------------|----------------|-------------------------|--------------------------|----------------|---------|
| Fifoot (2007) | 99 Mild to moderate | Dexamethasone 0.15 or 0.6 mg/kg, or prednisolone 1 mg/kg | Oral | Change in clinical croup score at 4 h | No difference between groups (p=0.47/9) |
| Geelhoed (1995) | 120 Moderate | Dexamethasone 0.15 or 0.30, or 0.60 mg/kg | Oral | Median duration of admission | No difference between groups (9 h in 0.15 mg/kg, 7 h in 0.30 mg/kg, 8 h in 0.6 mg/kg) |
| Alshehri (2005) | 72 Moderate | Dexamethasone 0.15 or 0.60 mg/kg | Oral | Change in clinical croup score at 12 h | No difference between groups (p=0.15) |
| Chob-Uppakarn (2007) | 41 Moderate to severe | Dexamethasone 0.15 or 0.60 mg/kg | Intravenous | Change in clinical croup score at 12 h | No difference between groups (p=0.40) |
Risks of corticosteroids

Although steroid treatment of children with croup is generally known to be safe, potential concerns exist with respect to possible adverse events. First, children treated with steroids after exposure to varicella virus can have an increased risk of developing complications of varicella, such as disseminated disease or bacterial superinfection. Published case-control studies addressing this issue have yielded conflicting results. Whereas in one study, an increase in risk of complicated varicella in immunocompetent children treated with steroids was noted,\(^\text{106}\) in another this finding was not seen.\(^\text{107}\) The US Food and Drug Administration, the American Academy of Pediatrics, and the American Academy of Allergy and Immunology advise caution in the use of steroids in children who have been exposed to varicella virus.\(^\text{108-111}\)

On a related issue, there is potential concern that corticosteroid use could prolong viral shedding; however, we were unable to find evidence that addresses this issue.

With steroid treatment, potential complications that have yet to be proven include bacterial tracheitis,\(^\text{8,17}\) pneumonia, and gastrointestinal bleeding.\(^\text{8,112-114}\) Bacterial tracheitis has been proposed to be related to previously unsuspected immune dysfunction.\(^\text{117}\) With respect to pneumonia, in a retrospective case review of 3577 immune-suppressed stem-cell transplant recipients, the most important factor associated with development of parainfluenza pneumonia was dose of corticosteroid at the time of infection acquisition.\(^\text{116}\) Gastrointestinal bleeding would seem to be unlikely in otherwise healthy children, but it could be more of a concern in a child with severe disease who requires care in the intensive-care unit, endotracheal intubation, and repeated high doses of steroids.\(^\text{114}\)

Epinephrine

In children with moderate-to-severe croup, treatment with epinephrine via a nebuliser has a long history and has been well studied (table 5). Using historical comparisons, the administration of epinephrine in children with severe croup has been reported to have reduced the number needing intubation or tracheotomy by a substantial amount.\(^\text{120}\) Nebulised racemic epinephrine (2-25%), compared with placebo, improved croup scores within 10–30 min of initiation of treatment in three randomised controlled trials.\(^\text{117-119}\) In a fourth placebo-controlled trial, a clear benefit was not recorded; however, this trial was not well-designed nor well-reported.\(^\text{121}\) Objective pathophysiological measures of severity have also shown substantial improvement after epinephrine treatment in five prospective cohort studies.\(^\text{52,72,122}\) Clinical effect is sustained for at least 1 h.\(^\text{52,72,109,120,121}\) but it is essentially gone within 2 h of administration.\(^\text{119}\) Reassuringly, as the effect of epinephrine wears off, the patient’s symptoms return—on average—to their baseline severity and do not seem to worsen.\(^\text{120,121}\) Combined data from five prospective clinical trials in outpatients treated with epinephrine and dexamethasone (or budesonide) who were observed for 2–4 h are also reassuring. Of 253 children, only 12 (5%) who were discharged home returned for care within 48–72 h and only six of these were admitted to hospital (2%). No children had adverse outcomes.\(^\text{47,124-127}\) This prospectively derived data along with findings of two retrospective cohort studies provide favourable support for children to be safely discharged home after treatment with epinephrine, as long as their symptoms have not recurred within 2–4 h of treatment.\(^\text{128,129}\)

The administration of one dose at a time of nebulised epinephrine to children has not been associated with any adverse effects nor a clinically significant increase in either heart rate or blood pressure.\(^\text{7,9,13,19,122,129}\) The conclusions of a critical review of seven clinical trials of 238 children treated with nebulised epinephrine (1/1000, with 184 patients receiving doses of 3 mL or greater) for either croup or acute bronchiolitis noted that epinephrine was a safe treatment and identified only mild side-effects, including, most frequently, tachycardia and pallor.\(^\text{120}\)

One case report has been published of a previously healthy child with severe croup who developed ventricular tachycardia and myocardial infarction after treatment with three doses of epinephrine via nebuliser within 1 h.\(^\text{122}\) Racemic epinephrine has traditionally been used to treat children with croup. However, epinephrine 1/1000 is as effective and safe as the racemate form, as shown by...
favourably, and so we have no evidence that prophylactic antibiotics are needed for the prevention of superinfections, such as bacterial tracheitis and pneumonia, or of croup. We retrieved no controlled trials of the effectiveness of any of these drugs in the treatment of croup with our search of the literature. The use of analgesics or antipyretics is reasonable for the benefit of reduction of fever or discomfort in children with croup. Most types of croup have a viral cause. Although so-called superinfections, such as bacterial tracheitis and pneumonia, are described, the rare frequency (<1 per 1000 cases of croup) makes use of prophylactic antibiotics unreasonable. No physiologically rational basis exists for use of antitussives or decongestants, and they should not be administered to children with croup. Similarly, in view of the pathophysiology of croup as an upper-airway disease, there is no clear reason to use short-acting β2 agonists for treatment of the disease.

**Indications for admission and discharge from medical care**

Although most children with croup can be managed safely as outpatients, little published evidence is available to guide clinicians as to which individuals should be admitted to hospital. Data from a retrospective cohort of 527 children admitted to Royal Children’s Hospital, Melbourne, for persistent stridor at rest (before routine treatment with corticosteroids) showed that those with persistent sternal indrawing at presentation to an emergency department had a 6% risk for endotracheal intubation, whereas those without sternal and chest-wall indrawing recovered rapidly without any specific treatment. In a study comparing dexamethasone with placebo, recorded reductions in admissions in the dexamethasone-treated group were first noted 3 h later, with increasing differences shown up to 10 h after treatment. The rate of admission in the dexamethasone-treated group was half that of those given placebo. This finding suggests that observation in an emergency department for at least 3 h, and ideally up to 10 h after treatment with corticosteroids, would reduce admission rates, presumably as the beneficial effects of corticosteroids become evident with time. In a published report looking at length of stay in the emergency department and admission, a substantial reduction was recorded in admissions after implementation of a clinical pathway mandating 6 h of observation in the emergency department after corticosteroid treatment before a child with croup was admitted to hospital. Based on this evidence and combined with expert opinion, the Alberta Medical Association clinical pathway committee has developed and implemented the management algorithm outlined in the figure.

**Conclusion**

After 50 years of controversy, corticosteroids have been firmly established as the treatment of choice for children with croup. Although comparatively fewer reports have been published on epinephrine, sufficient data exist to support the drug’s role in short-term symptom relief until corticosteroids take effect. Conversely, after more than a century of use, definitive evidence is available to show the ineffectiveness of mist. Apart from heliox, no new therapeutic interventions are on the horizon. Nonetheless, corticosteroids and epinephrine have greatly reduced health-care use and enhanced outcomes in children with croup. Although effective treatment for croup is well-established, several mysteries remain unexplained with respect to the cause and pathophysiology of the disease. Exploration of these questions could ultimately yield novel and even more effective treatments or vaccines.

**Conflict of interest statement**

We declare that we have no conflict of interest. DJ received an unrestricted research grant in 1993 from Astra Pharma, Mississauga, ON, Canada, to undertake a randomised controlled trial comparing nebulised budesonide, intramuscular dexamethasone, and placebo for moderately severe croup.

**References**

1. Stool S. Croup syndrome: historical perspective. *Pediatr Infect Dis J* 1988; 7: S157–61.

---

**Table 5: Selected randomised controlled trials of nebulised epinephrine versus placebo in the treatment of croup**

| Patients (n) | Croup severity | Epinephrine dose | Primary outcome | Results |
|--------------|----------------|------------------|----------------|---------|
| Taussig (1975) | 13 | Moderate to severe | 0.25–5 mL (by weight) of 2.25% epinephrine | Clinical croup score 10 min after treatment | Improvement (p=0.011) |
| Kristjansson (1994) | 54 | Mild to moderately severe | Racemic epinephrine (20 mg/mL) at 0.5 mg/kg | Clinical croup score 30 min after treatment | Greater improvement in epinephrine group (p=0.003) |
| Westley (1978) | 20 | Moderate | 0.5 mL of 2.25% epinephrine | Clinical croup score 10, 30, and 120 min after treatment | Greater improvement in epinephrine group at 10 and 30 min (p<0.1) No difference at 120 min |
60 Russel K, Wiebe N, Saenz A, et al. Glucocorticoids for croup. Cochrane Database Syst Rev 2004; 1: CD001955.
61 Johnson D, Williamson J. Telephone out patient (TOP) score: the derivation of a telephone follow-up assessment tool for children with croup. Pediatr Res 2003; 53: 185A.
62 Chan A, Langley J, LeBlanc J. Interobserver variability of croup scoring in clinical practice. J Paediatr Child Health 2001; 6: 347–51.
63 Johnson D. Croup: In: Rudolph M, Moyer V, eds. Clinical evidence, 12th edn. London: BMJ Publishing Group, 2004: 401–26.
64 Kaditis A, Wald E. Viral croup: current diagnosis and treatment. Pediatr Infect Dis J 1998; 17: 827–34.
65 Klassen T. Croup: a current perspective. Pediatr Clin North Am 1999; 46: 1367–78.
66 Brown J. The management of croup. Br Med Bull 2002; 61: 189–202.
67 Geelhoed G. Croup. Pediatr Pulmonol 1997; 23: 370–74.
68 Lavine E, Scolnik D. Lack of efficacy of humidification in the treatment of croup: why do physicians persist in using an unproven modality? Can J Emerg Med 2001; 3: 209–12.
69 Neto G, Kentab O, Klassen T, Osmond M. A randomized controlled trial of mist in the acute treatment of moderate croup. Acad Emerg Med 2002; 9: 873–79.
70 Scolnik D, Coates A, Stephens D, DaSilva Z, Lavine E, Schub S. Controlled delivery of very high vs low humidity vs mist therapy for croup in emergency departments. JAMA 2006; 295: 1274–80.
71 Bourdier D, Dawson K, Ferguson D. Humidification in viral croup: a controlled trial. Aust Paediatr J 1984; 20: 289–92.
72 Lenny W, Milner A. Treatment of acute viral croup. Pediatr Pulmonol 1997; 23: 370–74.
73 Henry R. Moist air in the treatment of laryngotracheitis. J Pediatr 1978; 53: 736–40.
74 Lenti P, Cheng K, Tannner M, Field D. Children with croup presenting with scalds. BMJ 1990; 301: 113.
75 Weber J, Chudnofsky C, Younger J, et al. A randomized comparison of helium-oxygen mixture (Heliox) and racemic epinephrine for the treatment of moderate to severe croup. Ann Emerg Med 1998; 32: 109–16.
76 Geelhoed G, Macdonald W. Oral dexamethasone in the treatment of croup: a randomized, double-blind trial. Pediatr Pulmonol 1995; 20: 355–61.
77 Klassen T, Feldman M, Watters L, Sutcliffe T, Rowe P. Nebulized budesonide for children with mild-to-moderate croup. N Engl J Med 1994; 331: 285–98.
78 Klassen T, Craig W, Moher D, et al. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. JAMA 1998; 279: 1629–32.
79 Rittichier K, Ledwith C. Outpatient treatment of moderate croup with dexamethasone: intramuscular versus oral dosing. Pediatrics 2000; 106: 1344–48.
80 Donaldson D, Polieski D, Knipple E, et al. Intramuscular versus oral dexamethasone for the treatment of moderate-to-severe croup: a randomized, double-blind trial. Acad Emerg Med 2003; 10: 16–21.
81 Amir L, Hubermann H, Halevi A, Mor M, Mimouni M, Waisman Y. Oral betamethasone versus intramuscular dexamethasone for the treatment of mild to moderate viral croup. Pediatr Emerg Care 2006; 22: 541–44.
82 Fifoot AA, Ting YJ. Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized, double-blind clinical trial. Pediatr Emerg Care Australas 2007; 19: 51–58.
83 Geelhoed G, Macdonald W. Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg. Pediatr Pulmonol 1995; 20: 362–68.
84 Alshehi M, Almegamsi T, Hammadi A. Efficacy of a small dose of oral dexamethasone in croup. Biomed Res 2005; 16: 65–72.
85 Chub-Uppakaro S, Sangsupawanich P. A randomized comparison of dexamethasone 0.15 mg/kg versus 0.6 mg/kg for the treatment of moderate to severe croup. Int J Pediatr Otorhinolaryngol 2007; 71: 473–77.
86 Pedersen L, Dahl M, Falk-Pedersen H, Larsen S. [Inhaled budesonide versus intramuscular dexamethasone in the treatment of pseudo-croup.] Ugeskr Laeger 1998; 160: 2253–56.
87 Cetinkaya F, Tufekci B, Kutlu G. A comparison of nebulized budesonide, and intramuscular, and oral dexamethasone for treatment of croup. J Pediatr Child Health 2006: 1587–612.
88 Geelhoed G. Budesonide offers no advantage when added to oral dexamethasone in the treatment of croup. Pediatr Emerg Care 2005; 21: 359–62.
89 Sparrow A, Geelhoed G. Prednisolone versus dexamethasone in croup: a randomised equivalence trial. Arch Dis Child 2006; 91: 580–83.
90 Qureshi S, Zariszyk A, Poirier M. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. J Pediatr 2001; 139: 20–26.
91 Schimmer B, Parker K. Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs—inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton L, Lazo J, Parker K, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. Columbus: McGraw-Hill, 2007: 1587–612.
92 Dowlle S, Bresse J. Severe varicella associated with steroid use. Pediatrics 1993; 92: 223–28.
93 Patel H, Macarthur C, Johnson D. Recent corticosteroid use and the risk of complicated varicella in otherwise immunocompetent children. Arch Pediatr Adolesc Med 1996; 150: 409–14.
94 Anon. Revised label warns of severe viral problems with corticosteroids. In: FDA Medical Bulletin, vol 21. Rockville: US Food and Drug Administration, 1991.
95 Anon. Draft position statement: inhaled corticosteroids and severe viral infections—news and notes. Milwaukee: American Academy and Immunology Committee on Drugs, 1992.
96 Anon. New drug not routinely recommended for healthy children with chickenpox. Ottawa: Canadian Pediatric Society, 1993.
97 Anon. Varicella-zoster infections. In: Halsey N, Hall CB, eds. 1997 red book: report of the committee on infectious diseases, 24th edn. Elk Grove Village: American Academy of Pediatrics, 1997: 762.
98 Lebel M, Freij B, Syrosigianopoulos G, et al. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo-controlled trials. N Engl J Med 1988; 319: 964–71.
113 Anene O, Meert K, Uy H, Simpson P, Sarmaia A. Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. Crit Care Med 1996; 24: 1666–73.

114 McIntyre P, Berkey C, King S, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. JAMA 1997; 278: 925–31.

115 Johnson D, Schuh S, Koren G, Jaffe D. Outpatient treatment of group with nebulized dexamethasone. Arch Pediatr Adolesc Med 1996; 150: 349–55.

116 Nichols W, Corey L, Gooley T, Davis C, Boekch M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 73–78.

117 Taussig L, Castro O, Beaudry P, Fox W, Bureau M. Treatment of group with nebulized dexamethasone. J Pediatr 1982; 101: 1028–31.

118 Rizos J, DiGravio B, Sehl M, Tallon J. The disposition of children with group treated with racemic epinephrine and dexamethasone in the emergency department. J Emerg Med 1998; 16: 533–39.

119 Westley C, Cotton E, Brooks J. Nebulized racemic epinephrine by IPPB for the treatment of group. Am J Dis Child 1975; 128: 790–93.

120 Kristjansson S, Berg-Kelly K, Winso E. Inhalation of racemic adrenaline in the treatment of mild and moderately severe group: clinical symptom score and oxygen saturation measurements for evaluation of treatment effects. Acta Paediatr 1994; 83: 1156–60.

121 Gardner H, Powell K, Roden V, Cherry J. The evaluation of racemic epinephrine in the treatment of infectious group. Pediatr 1973; 152: 68–71.

122 Prendergast M, Jones J, Hartman D. Racemic epinephrine in the treatment of laryngotracheitis--can we identify children for outpatient therapy? Am J Emerg Med 1994; 12: 613–16.

123 Corneli H, Bolte R. Outpatient use of racemic epinephrine in group. Am Fam Physician 1992; 46: 683–84.

124 Anene O, Meert K, Uy H, Simpson P, Sarmaia A. Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. Crit Care Med 1996; 24: 1666–73.

125 Ledwith C, Shea L, Mauro R. Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of group. Pediatr Emerg Care 1996; 12: 156–59.

126 Corneli H, Bolte R. Outpatient use of racemic epinephrine in group. Am Fam Physician 1992; 46: 683–84.

127 Anene O, Meert K, Uy H, Simpson P, Sarmaia A. Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. Crit Care Med 1996; 24: 1666–73.

128 Kristjansson S, Berg-Kelly K, Winso E. Inhalation of racemic adrenaline in the treatment of mild and moderately severe group: clinical symptom score and oxygen saturation measurements for evaluation of treatment effects. Acta Paediatr 1994; 83: 1156–60.

129 Kristjansson S, Berg-Kelly K, Winso E. Inhalation of racemic adrenaline in the treatment of mild and moderately severe group: clinical symptom score and oxygen saturation measurements for evaluation of treatment effects. Acta Paediatr 1994; 83: 1156–60.

130 Adair J, King W, Jordan W, Elwyn R. Ten-year experience with IPPB in the treatment of acute laryngotracheobronchitis. Anesth Analg 1971; 50: 68–71.

131 Adair J, King W, Jordan W, Elwyn R. Ten-year experience with IPPB in the treatment of acute laryngotracheobronchitis. Anesth Analg 1971; 50: 68–71.

132 Butte M, Nguyen B, Hutchison T, Wiggins J, Ziegler J. Pediatric myocardial infarction after racemic epinephrine administration. Pediatrics 1999; 104: e9.

133 Butte M, Nguyen B, Hutchison T, Wiggins J, Ziegler J. Pediatric myocardial infarction after racemic epinephrine administration. Pediatrics 1999; 104: e9.

134 Schuepp K, Straub D, Moller A, Wildhaber J. Deposition of aerosols with croup treated with racemic epinephrine and dexamethasone in the outpatient management of group. J Pediatr 1982; 101: 1028–31.

135 Schuepp K, Straub D, Moller A, Wildhaber J. Deposition of aerosols with croup treated with racemic epinephrine and dexamethasone in the outpatient management of group. J Pediatr 1982; 101: 1028–31.

136 Janssens H, Krijgsman A, Verbraak T, Hop W, de Jongste J, van der Bijl P. Aerosol delivery to ventilated infant and pediatric patients. Respir Care 2004; 49: 653–65.

137 Janssens H, Krijgsman A, Verbraak T, Hop W, de Jongste J, van der Bijl P. Aerosol delivery to ventilated infant and pediatric patients. Respir Care 2004; 49: 653–65.

138 Corneli H, Bolte R. Outpatient use of racemic epinephrine in group. Am Fam Physician 1992; 46: 683–84.

139 Corneli H, Bolte R. Outpatient use of racemic epinephrine in group. Am Fam Physician 1992; 46: 683–84.

140 Corneli H, Bolte R. Outpatient use of racemic epinephrine in group. Am Fam Physician 1992; 46: 683–84.

141 Corneli H, Bolte R. Outpatient use of racemic epinephrine in group. Am Fam Physician 1992; 46: 683–84.